Grants and Contracts Details
Description
TITLE:
A PHASE Ill, MUL TICENTER, RANDOMIZED STUDY OF
ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN
COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND
BEVACIZUMAB FOR PATIENTS WITH NEWLY-DIAGNOSED
STAGE Ill OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR
PRIMARY PERITONEAL CANCER
Objectives and Endpoints
This study will evaluate the efficacy, safety, and pharmacokinetics of atezolizumab
administered with paclitaxel+carboplatin+bevacizumab compared with
placebo+ paclitaxel+carboplatin+ bevacizumab in patients with newly-diagnosed, untreated
ovarian, fallopian tube, and/or primary peritoneal cancer.
| Status | Finished |
|---|---|
| Effective start/end date | 11/29/17 → 7/13/23 |
Funding
- Gynecological Oncology Group Foundation Incorporated: $272,309.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.